Simris Group AB
Develops novel cyanobacteria-based payloads for Antibody-Drug Conjugates to treat cancer.
SIMRIS | ST
Overview
Corporate Details
- ISIN(s):
- SE0008091656 (+1 more)
- LEI:
- 529900P0ACIS2UI3ZX27
- Country:
- Sweden
- Address:
- Herrestadsvägen 24A, 276 50 HAMMENHÖG
- Website:
- https://simris.com/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
Simris Group AB is a biotechnology company specializing in the development of next-generation payloads for Antibody-Drug Conjugates (ADCs) to advance cancer treatment. The company leverages its proprietary platform, which is built upon the world's largest cyanobacterial strain library and deep expertise in bioconjugation technologies. Simris engineers and develops novel, IP-protected payloads using cyanobacterial toxin engineering. These payloads are designed to improve the therapeutic window of ADCs by enhancing their potency, safety, and selectivity compared to conventional options, with the goal of revolutionizing the therapeutic potential of ADC treatments in oncology.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Simris Group AB filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Simris Group AB via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
